Interferon- α can alter the Lytic Susceptibility of Murine Bladder Transitional Cell Carcinoma (MBT-2) by their Original Poor Specific Cytotoxic Tumor Infiltrating Lymphocytes
- 1 February 1992
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 147 (2) , 523-527
- https://doi.org/10.1016/s0022-5347(17)37293-2
Abstract
Fresh isolated or short term in vitro cultured tumor infiltrating lymphocytes derived from MBT-2 tumor possess little specific cytotoxicity on MBT-2 cells despite the presence of low (10 units/ml.), moderate (500 units/ml.), or high (1000 units/ml.) dose interleukin-2 and irradiated tumor cells; however the lytic susceptibility of the MBT-2 cells and their expression of MHC class I antigen can be significantly enhanced if the tumor cells are preincubated with interferon-alpha for 24 hours. But the specific antitumor activity of tumor infiltrating lymphocytes cannot be further augmented by coculturing them with irradiated interferon-alpha pretreated MBT-2 tumor cells. In vivo experiments by subcutaneous peritumor injection of interferon-alpha (500 units/ml.) combined with interleukin-2 (500 units/ml.) can suppress the tumor growth of those three-day inoculated MBT-2 cells significantly but not on those already established tiny tumors. We therefore concluded that interferon-alpha can alter the specific antitumor activity of tumor infiltrating lymphocytes chiefly through its modulating effect on the target tumor cells instead of the tumor infiltrating lymphocytes.Keywords
This publication has 12 references indexed in Scilit:
- Effects of Murine Tumor Class I Major Histocompatibility Complex Expression on Antitumor Activity of Tumor-Infiltrating LymphocytesJNCI Journal of the National Cancer Institute, 1990
- Experience with the Use of High-Dose Interleukin-2 in the Treatment of 652 Cancer PatientsAnnals of Surgery, 1989
- Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic MelanomaNew England Journal of Medicine, 1988
- Augmented Tumor-Associated Antigen Expression by Interferons1JNCI Journal of the National Cancer Institute, 1988
- Immunotherapy of a murine tumor with interleukin 2. Increased sensitivity after MHC class I gene transfection.The Journal of Experimental Medicine, 1987
- Recombinant Interferon Enhances Monoclonal Antibody-Targeting of Carcinoma Lesions in VivoScience, 1987
- The role of class I histocompatibility antigens in the regulation of T-cell activation.Proceedings of the National Academy of Sciences, 1987
- Loss of HLA‐A,B,C and de novo expression of HLA‐D in colorectal cancerInternational Journal of Cancer, 1986
- Heterogenous expression of cell-surface antigens in normal epithelia and their tumours, revealed by monoclonal antibodiesBritish Journal of Cancer, 1985
- Prognostic significance of microscopic structure of gastric carcinomas and their regional lymph nodesCancer, 1971